Neprilysin Confers Genetic Susceptibility to Alzheimer’s Disease in Han Chinese

Molecular Neurobiology

Volumn 53, Issue 7, 2016, Pages 4883-4892

  Wang, Hui Zhen ^a   Bi, Rui ^a   Zhang, Deng Feng ^a,b   Li, Guo Dong ^a,b   Ma, Xiao Hong ^c   Fang, Yiru ^d   Li, Tao ^c   Zhang, Chen ^d   Yao, Yong Gang ^a,b,e  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SICHUAN UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e Shenzhen Fundamental Research Institutions   (China)

Author keywords

Alzheimer s disease; A degrading enzyme; Chinese; Genetic susceptibility; Neprilysin

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GELATINASE B; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ARTICLE; BONFERRONI CORRECTION; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HAN CHINESE; HUMAN; IDE GENE; MAJOR CLINICAL STUDY; MALE; MMP 9 GENE; NEP GENE; PATHOGENESIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; ASIAN CONTINENTAL ANCESTRY GROUP; DATA MINING; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; PROCEDURES; PROTEIN DOMAIN;

ALZHEIMER DISEASE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; DATA MINING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEPRILYSIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN INTERACTION DOMAINS AND MOTIFS;

EID: 84941338476     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9411-z     Document Type: Article

References (61)

1. Dickson TC, Vickers JC (2001) The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer’s disease. Neuroscience 105(1):99–107
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297(5580):353–356
3. Tanzi RE (2012) The genetics of Alzheimer disease. Cold Spring Harbr Perspect Med 2(10)
4. St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG et al (1987) The genetic defect causing familial Alzheimer’s disease maps on chromosome 21. Science 235(4791):885–890
5. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD et al (1995) Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 269(5226):973–977
6. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C et al (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 375(6534):754–760
7. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 90(5):1977–1981
8. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, DeStafano AL, Bis JC et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 45(12):1452–1458
9. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V et al (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet 41(10):1088–1093
10. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML et al (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43(5):429–435
11. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD et al (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet 43(5):436–441
12. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV et al (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303(18):1832–1840
13. Wang HZ, Bi R, Hu QX, Xiang Q, Zhang C, Zhang DF, Zhang W, Ma X et al (2014) Validating GWAS-identified risk loci for Alzheimer’s disease in Han Chinese populations. Mol Neurobiol. doi:10.1007/s12035-014-9015-z
14. Zhang DF, Fan Y, Wang D, Bi R, Zhang C, Fang Y, Yao YG (2015) PLD3 in Alzheimer’s disease: a modest effect as revealed by updated association and expression analyses. Mol Neurobiol. doi:10.1007/s12035-015-9353-5
15. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E et al (2001) Metabolic regulation of brain Abeta by neprilysin. Science 292(5521):1550–1552
16. McDermott JR, Gibson AM (1997) Degradation of Alzheimer’s beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res 22(1):49–56
17. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A et al (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273(49):32730–32738
18. Kurochkin IV, Goto S (1994) Alzheimer’s beta-amyloid peptide specifically interacts with and is degraded by insulin degrading enzyme. FEBS Lett 345(1):33–37
19. Backstrom JR, Lim GP, Cullen MJ, Tokes ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16(24):7910–7919
20. Morelli L, Llovera RE, Mathov I, Lue LF, Frangione B, Ghiso J, Castano EM (2004) Insulin-degrading enzyme in brain microvessels: proteolysis of amyloid {beta} vasculotropic variants and reduced activity in cerebral amyloid angiopathy. J Biol Chem 279(53):56004–56013
21. Miners JS, Van Helmond Z, Chalmers K, Wilcock G, Love S, Kehoe PG (2006) Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol 65(10):1012–1021
22. Turner AJ, Isaac RE, Coates D (2001) The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. BioEssays 23(3):261–269
23. Poduslo SE, Yin X, Hargis J, Brumback RA, Mastrianni JA, Schwankhaus J (1999) A familial case of Alzheimer’s disease without tau pathology may be linked with chromosome 3 markers. Hum Genet 105(1-2):32–37
24. Yasojima K, Akiyama H, McGeer EG, McGeer PL (2001) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci Lett 297(2):97–100
25. Carpentier M, Robitaille Y, DesGroseillers L, Boileau G, Marcinkiewicz M (2002) Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61(10):849–856
26. Clarimon J, Munoz FJ, Boada M, Tarraga L, Sunyer J, Bertranpetit J, Comas D (2003) Possible increased risk for Alzheimer’s disease associated with neprilysin gene. J Neural Transm 110(6):651–657
27. Blomqvist ME, McCarthy S, Blennow K, Andersson B, Prince JA (2010) Evaluation of neprilysin sequence variation in relation to CSF beta-Amyloid levels and Alzheimer disease risk. Int J Mol Epidemiol Genet 1(1):47–52
28. Fu Y, Li AF, Shi JJ, Tang MN, Guo YB, Zhao ZH (2009) Lack of association of neprilysin gene polymorphisms with Alzheimer’s disease in a southern Chinese community. Int Psychogeriatr 21(2):354–358
29. Giedraitis V, Kilander L, Degerman-Gunnarsson M, Sundelof J, Axelsson T, Syvanen AC, Lannfelt L, Glaser A et al (2009) Genetic analysis of Alzheimer’s disease in the Uppsala longitudinal study of adult Men. Dement Geriatr Cogn Disord 27(1):59–68
30. Sakai A, Ujike H, Nakata K, Takehisa Y, Imamura T, Uchida N, Kanzaki A, Yamamoto M et al (2004) Association of the neprilysin gene with susceptibility to late-onset Alzheimer’s disease. Dement Geriatr Cogn Disord 17(3):164–169
31. Shi J, Zhang S, Tang M, Ma C, Zhao J, Li T, Liu X, Sun Y et al (2005) Mutation screening and association study of the neprilysin gene in sporadic Alzheimer’s disease in Chinese persons. J Gerontol A: Biol Med Sci 60(3):301–306
32. Wood LS, Pickering EH, McHale D, Dechairo BM (2007) Association between neprilysin polymorphisms and sporadic Alzheimer’s disease. Neurosci Lett 427(2):103–106
33. Ghosh S, Watanabe RM, Valle TT, Hauser ER, Magnuson VL, Langefeld CD, Ally DS, Mohlke KL et al (2000) The Finland-united states investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. Am J Hum Genet 67(5):1174–1185
34. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG et al (2000) Evidence for genetic linkage of Alzheimer’s disease to chromosome 10q. Science 290(5500):2302–2303
35. Ogawa W, Shii K, Yonezawa K, Baba S, Yokono K (1992) Affinity purification of insulin-degrading enzyme and its endogenous inhibitor from rat liver. J Biol Chem 267(2):1310–1316
36. Bian L, Yang JD, Guo TW, Sun Y, Duan SW, Chen WY, Pan YX, Feng GY et al (2004) Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese. Neurology 63(2):241–245
37. Bjork BF, Katzov H, Kehoe P, Fratiglioni L, Winblad B, Prince JA, Graff C (2007) Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. Neurobiol Aging 28(9):1374–1380
38. Carrasquillo MM, Belbin O, Zou F, Allen M, Ertekin-Taner N, Ansari M, Wilcox SL, Kashino MR et al (2010) Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer’s disease. PLoS One 5(1):e8764
39. Blomqvist ME, Silburn PA, Buchanan DD, Andreasen N, Blennow K, Pedersen NL, Brookes AJ, Mellick GD et al (2004) Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics 5(2):115–119
40. Edland SD, Wavrant-De Vriese F, Compton D, Smith GE, Ivnik R, Boeve BF, Tangalos EG, Petersen RC et al (2003) Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer’s disease: evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett 345(1):21–24
41. Ertekin-Taner N, Allen M, Fadale D, Scanlin L, Younkin L, Petersen RC, Graff-Radford N, Younkin SG et al (2004) Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzheimer disease. Hum Mutat 23(4):334–342
42. Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K, Brookes AJ (2003) Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat 22(5):363–371
43. Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, Compton D, Spurlock G et al (2001) Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer’s disease. Hum Genet 109(6):646–652
44. Boussaha M, Hannequin D, Verpillat P, Brice A, Frebourg T, Campion D (2002) Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer’s disease. Neurosci Lett 329(1):121–123
45. Nowotny P, Hinrichs AL, Smemo S, Kauwe JS, Maxwell T, Holmans P, Hamshere M, Turic D et al (2005) Association studies between risk for late-onset Alzheimer’s disease and variants in insulin degrading enzyme. Am J Med Genet B Neuropsychiatr Genet 136B(1):62–68
46. Sakai A, Ujike H, Nakata K, Takehisa Y, Imamura T, Uchida N, Kanzaki A, Yamamoto M et al (2004) No association between the insulin degrading enzyme gene and Alzheimer’s disease in a Japanese population. Am J Med Genet B Neuropsychiatr Genet 125B(1):87–91
47. Kamat PK, Swarnkar S, Rai S, Kumar V, Tyagi N (2014) Astrocyte mediated MMP-9 activation in the synapse dysfunction: an implication in Alzheimer disease. Ther Targets Neurol Dis 1(1)
48. Helbecque N, Hermant X, Cottel D, Amouyel P (2003) The role of matrix metalloproteinase-9 in dementia. Neurosci Lett 350(3):181–183
49. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34(7):939–944
50. Bi R, Zhao L, Zhang C, Lu W, Feng JQ, Wang Y, Ni J, Zhang J et al (2014) Association of the LRRK2 genetic variants with Alzheimer’s disease in Han Chinese individuals. Neurobiol Aging 35(2):444.e5
51. Li X, Zhang W, Zhang C, Gong W, Tang J, Yi Z, Wang D, Lu W et al (2014) No association between genetic variants of the LRRK2 gene and schizophrenia in Han Chinese. Neurosci Lett 566:210–215
52. Zhang W, Xiao MS, Ji S, Tang J, Xu L, Li X, Li M, Wang HZ et al (2014) Promoter variant rs2301228 on the neural cell adhesion molecule 1 gene confers risk of schizophrenia in Han Chinese. Schizophr Res 160(1-3):88–96
53. Helisalmi S, Hiltunen M, Vepsalainen S, Iivonen S, Mannermaa A, Lehtovirta M, Koivisto AM, Alafuzoff I et al (2004) Polymorphisms in neprilysin gene affect the risk of Alzheimer’s disease in Finnish patients. J Neurol Neurosurg Psychiatry 75(12):1746–1748
54. Gauderman WJ (2002) Sample size requirements for matched case-control studies of gene-environment interaction. Stat Med 21(1):35–50
55. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P et al (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81(3):559–575
56. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265
57. Simpson JE, Ince PG, Shaw PJ, Heath PR, Raman R, Garwood CJ, Gelsthorpe C, Baxter L et al (2011) Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer’s pathology and APOE genotype. Neurobiol Aging 32(10):1795–1807
58. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW (2004) Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A 101(7):2173–2178
59. Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, Benita Y, Cotsapas C, Daly MJ, International Inflammatory Bowel Disease Genetics et al (2011) Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. PLoS Genet 7(1):e1001273
60. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR et al (2008) Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 65(1):45–53
61. Hellstrom-Lindahl E, Ravid R, Nordberg A (2008) Age-dependent decline of neprilysin in Alzheimer’s disease and normal brain: inverse correlation with a beta levels. Neurobiol Aging 29(2):210–221